Skip to main content
. 2016 May 6;7(27):41488–41504. doi: 10.18632/oncotarget.9206

Figure 7. Combinations of TRAIL with SMAC mimetics or mithramycin-A also overcome TRAIL resistance under normoxic conditions.

Figure 7

A–F. HT29 and SW480 cells were grown under normoxic (21% O2) and hypoxic (0.5% O2) conditions for 18 h in the presence and absence of BV6 (6.25 μM) or LCL161 (HT29: 12.5 μM; SW480: 25 μM) or mithramycin-A (125 nM). Thereafter, cells were treated with the indicated concentrations of TRAIL for another 18 h. Cell viability was measured using MTT staining. Values are means ± SEM from three experiments. MithA, mithramycin-A.